从2026年开始, Novartis将在得克萨斯州丹顿建造一座23B美元的放射治疗工厂, 制造Pluvicto和Lutathera等癌症药物。 Novartis will build a $23B U.S. radioligand therapy plant in Denton, Texas, starting in 2026, to make cancer drugs like Pluvicto and Lutathera.

Novartis将在得克萨斯州丹顿建造一个46 000平方英尺的放射和治疗制造设施,这是美国首个和第五个,是美国230亿美元生产扩张的一部分。 Novartis will build a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, its first in the state and the fifth in the U.S., as part of a $23 billion expansion of U.S. production. 2026年开始施工,预计到2028年全面投入运行。 Construction starts in 2026, with full operation expected by 2028. 该网站将生产Pluvicto和Lutathera等有针对性的癌症治疗,支持对下一代疗法日益增长的需求。 The site will produce targeted cancer treatments like Pluvicto and Lutathera, supporting growing demand for next-generation therapies. 该项目将在生物工程、制造、质量控制和操作方面创造就业机会,补充新泽西、印第安纳、加利福尼亚和佛罗里达的现有设施。 The project will create jobs in bioengineering, manufacturing, quality control, and operations, complementing existing facilities in New Jersey, Indiana, California, and Florida.